Strategies for Cytokine Modification and Stem Cell Mobilization for Acute Myocardial Infarction

[1]  W. O’Neill,et al.  The year in interventional cardiology. , 2004, Journal of the American College of Cardiology.

[2]  A. Arai,et al.  Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. , 2005, Journal of the American College of Cardiology.

[3]  B. Wood,et al.  Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte–colony‐stimulating factor by single‐dose administration of AMD3100, a CXCR4 antagonist , 2005, Transfusion.

[4]  I. Komuro,et al.  G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes , 2005, Nature Medicine.

[5]  S. Ogawa,et al.  Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction. , 2005, Cardiovascular research.

[6]  藤田 淳.  Non-hematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction , 2005 .

[7]  William W O'Neill,et al.  The year in interventional cardiology. , 2005, Journal of the American College of Cardiology.

[8]  H. Okano,et al.  Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. , 2004, Blood.

[9]  M. Pan,et al.  Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy. , 2004, American heart journal.

[10]  S. Homma,et al.  Myocardial neovascularization by bone marrow angioblasts results in cardiomyocyte regeneration. , 2004, American journal of physiology. Heart and circulatory physiology.

[11]  Bernd Hertenstein,et al.  Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial , 2004, The Lancet.

[12]  M. Arai,et al.  Acceleration of the Healing Process and Myocardial Regeneration May Be Important as a Mechanism of Improvement of Cardiac Function and Remodeling by Postinfarction Granulocyte Colony–Stimulating Factor Treatment , 2004, Circulation.

[13]  H. Kang,et al.  Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomized clinical trial , 2004 .

[14]  E. Topol,et al.  First human randomized trial of G-CSF stem cell mobilization to treat large acute myocardial infarction—preliminary results of a pilot study , 2004 .

[15]  David A. Williams,et al.  Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts , 2004, Nature.

[16]  J. Dipersio,et al.  Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Hyun-Jai Cho,et al.  Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial , 2004, The Lancet.

[18]  A. Zeiher,et al.  ransplantation of Progenitor Cells nd Regeneration Enhancement n Acute Myocardial Infarction , 2004 .

[19]  B. Wood,et al.  Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. , 2003, Blood.

[20]  Eric J Topol,et al.  Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy , 2003, The Lancet.

[21]  J. Lévesque,et al.  Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. , 2003, The Journal of clinical investigation.

[22]  I. Weissman,et al.  Little Evidence for Developmental Plasticity of Adult Hematopoietic Stem Cells , 2002, Science.

[23]  I. Petit,et al.  Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. , 2002, Experimental hematology.

[24]  B. Gersh,et al.  And the answer is, it doesn't much matter. , 2002, Circulation.

[25]  P. Anversa,et al.  Chimerism of the transplanted heart. , 2002, The New England journal of medicine.

[26]  Federica Limana,et al.  Mobilized bone marrow cells repair the infarcted heart, improving function and survival , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Entman,et al.  Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. , 2001, The Journal of clinical investigation.

[28]  S. Chierchia,et al.  Influence of treatment delay on long-term left ventricular function in patients with acute myocardial infarction successfully treated with primary angioplasty. , 2001, American heart journal.

[29]  S. Homma,et al.  Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function , 2001, Nature Medicine.

[30]  John S. Beech,et al.  Resolution of Stroke Deficits Following Contralateral Grafts of Conditionally Immortal Neuroepithelial Stem Cells , 2001, Stroke.

[31]  S. Sell,et al.  Heterogeneity and plasticity of hepatocyte lineage cells , 2001, Hepatology.

[32]  D. Kelvin,et al.  The human hematopoietic stem cell compartment is heterogeneous for CXCR4 expression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Schenkein,et al.  A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma , 2000, Bone Marrow Transplantation.

[34]  H. White,et al.  Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? , 2000, Journal of the American College of Cardiology.

[35]  Edward J. Fuchs,et al.  Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers , 2000, Antimicrobial Agents and Chemotherapy.

[36]  M. Le Bousse-Kerdilès,et al.  Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival. , 2000, Blood.

[37]  F. Werf.  Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial , 1999, The Lancet.

[38]  A. Grañena,et al.  Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. , 1999, Blood.

[39]  J. Isner,et al.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. , 1999, Circulation research.

[40]  E. De Clercq,et al.  Bicyclams, Selective Antagonists of the Human Chemokine Receptor CXCR4, Potently Inhibit Feline Immunodeficiency Virus Replication , 1999, Journal of Virology.

[41]  C. Bordignon,et al.  Expression of CXCR4, the receptor for stromal cell‐derived factor‐1 on fetal and adult human lymphohematopoietic progenitors , 1999, European journal of immunology.

[42]  R. Haas,et al.  The human immunodeficiency virus (HIV)-type 1 coreceptor CXCR-4 (fusin) is preferentially expressed on the more immature CD34+ hematopoietic stem cells , 1998, Annals of Hematology.

[43]  J. Radford,et al.  Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  E. De Clercq,et al.  Determinants for Sensitivity of Human Immunodeficiency Virus Coreceptor CXCR4 to the Bicyclam AMD3100 , 1998, Journal of Virology.

[45]  S. Rafii,et al.  The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. , 1998, Blood.

[46]  B. Meisenberg,et al.  A combination of low‐dose cyclophosphamide and colony‐stimulating factors is more cost‐effective than granulocyte‐colony‐stimulating factors alone in mobilizing peripheral blood stem and progenitor cells , 1998, Transfusion.

[47]  E. Shpall,et al.  Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. , 1997, Blood.

[48]  E. De Clercq,et al.  Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. , 1997, Antiviral research.

[49]  M. Simoons,et al.  A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. , 1997, The New England journal of medicine.

[50]  P. Bierman,et al.  Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  E. Copelan,et al.  Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  T. Springer,et al.  The Chemokine SDF-1 Is a Chemoattractant for Human CD34+ Hematopoietic Progenitor Cells and Provides a New Mechanism to Explain the Mobilization of CD34+ Progenitors to Peripheral Blood , 1997, The Journal of experimental medicine.

[53]  R. Möhle,et al.  Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis. , 1994, Bone marrow transplantation.

[54]  N. Adzick,et al.  Wound Healing: Biochemical and Clinical Aspects , 1992 .

[55]  I. K. Cohen,et al.  Wound Healing: Biochemical & Clinical Aspects , 1992 .

[56]  C. March,et al.  Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms , 1990, Cell.

[57]  David A. Williams,et al.  Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor , 1990, Cell.

[58]  K. Zsebo,et al.  Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium , 1990, Cell.

[59]  K. Zsebo,et al.  Primary structure and functional expression of rat and human stem cell factor DNAs , 1990, Cell.

[60]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.